ストックスクリーナーアプリを入手
5.01
5.92%
0.28
アフターアワーズ：
4.94
-0.07
-1.40%
前日終値:
$4.73
開ける：
$4.71
24時間の取引高:
718.63K
Relative Volume:
0.63
時価総額：
$321.93M
収益：
-
当期純損益:
$-27.03M
株価収益率:
-8.9464
EPS:
-0.56
ネットキャッシュフロー:
$-23.97M
1週間 パフォーマンス:
-6.00%
1か月 パフォーマンス:
-32.21%
6か月 パフォーマンス:
+130.88%
1年 パフォーマンス:
+144.39%
1日の値動き範囲:
$4.66
$5.12
1週間の範囲:
$4.60
$5.33
52週間の値動き範囲:
$1.30
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
名前
Corvus Pharmaceuticals Inc
セクター
電話
(650) 900-4520
住所
863 MITTEN ROAD, BURLINGAME, CA
CRVS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
5.01 | 321.93M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-02 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-18 | 開始されました | Oppenheimer | Outperform |
| 2021-12-01 | 再開されました | Jefferies | Buy |
| 2021-05-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-02-10 | ダウングレード | Mizuho | Buy → Neutral |
| 2019-09-12 | 開始されました | Mizuho | Buy |
| 2019-05-29 | 開始されました | ROTH Capital | Buy |
| 2017-08-24 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | 開始されました | Credit Suisse | Outperform |
| 2016-04-18 | 開始されました | Guggenheim | Buy |
すべてを表示
Corvus Pharmaceuticals Inc (CRVS) 最新ニュース
CRVS’s Stock Market Adventure: -8.04% YTD Growth Amidst Volatility - The InvestChronicle
Corvus Pharmaceuticals (NASDAQ: CRVS) Announces Positive Interim Data from Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisOn January 13, 2025, Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company, released encouraging int - Defense World
HC Wainwright Reiterates "Buy" Rating for Corvus Pharmaceuticals (NASDAQ:CRVS) - MarketBeat
HC Wainwright & Co. Initiates Coverage of Corvus Pharmaceuticals (CRVS) with Buy Recommendation - MSN
Corvus Pharmaceuticals Reports Promising Interim Data on Soquelitinib - TipRanks
Corvus reports hopeful data on eczema drug trial - Investing.com India
Corvus reports hopeful data on eczema drug trial By Investing.com - Investing.com Australia
Corvus Pharmaceuticals Announces Data from Cohort 2 of - GlobeNewswire
Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - Yahoo Finance
50,221 Shares in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Bought by Jane Street Group LLC - Defense World
Geode Capital Management LLC Purchases 102,869 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - MarketBeat
Geode Capital Management LLC Increases Stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - Defense World
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Corvus Pharmaceuticals CEO to Present Corporate Overview at J.P. Morgan Healthcare Conference - StockTitan
We're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn - Yahoo Finance
What is HC Wainwright’s Forecast for CRVS FY2024 Earnings? - Defense World
What is HC Wainwright's Forecast for CRVS FY2024 Earnings? - MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives $12.83 Consensus Price Target from Analysts - Defense World
Analysts Set Expectations for CRVS Q4 Earnings - Defense World
Drug Innovator Launches Pivotal Cancer Trial Breakthrough - Streetwise Reports
What is HC Wainwright's Estimate for CRVS Q4 Earnings? - MarketBeat
State Street Corp Purchases 57,943 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - Defense World
Corvus Pharmaceuticals (NASDAQ:CRVS) Now Covered by Analysts at HC Wainwright - Defense World
Corvus wins new buy from H.C. Wainwright despite recent selloff - MSN
Corvus stock wins new buy at H.C. Wainwright (CRVS:NASDAQ) - Seeking Alpha
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
This Kopin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Corvus Pharmaceuticals (NASDAQ:CRVS) Coverage Initiated at HC Wainwright - MarketBeat
When the Price of (CRVS) Talks, People Listen - Stock Traders Daily
XTX Topco Ltd Buys Shares of 14,086 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - Defense World
Corvus falls after early-stage data for eczema therapy - MSN
Corvus Pharmaceuticals (NASDAQ:CRVS) Announces Interim Data from Atopic Dermatitis TrialBURLINGAME, Calif. – Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) disclosed key interim data from its randomized, double-blind, placebo-controlled Phase 1 cl - Defense World
Corvus: Early Atopic Dermatitis Data Signals More Questions Than Answers (Rating Downgrade) - Seeking Alpha
Corvus Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:CRVS) - Defense World
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday? - AOL
Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting (CRVS) - Seeking Alpha
Crude Oil Gains Over 1%, General Mills Shares Fall - Benzinga
Dow Surges 150 Points, US Current Account Deficit Widens In Q3 - Benzinga
Stock Traders Buy High Volume of Put Options on Corvus Pharmaceuticals (NASDAQ:CRVS) - MarketBeat
Corvus stock falls after eczema trial data (CRVS:NASDAQ) - Seeking Alpha
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Corvus Pharmaceuticals Reports Promising Phase 1 Data and Financial Boost - TipRanks
Corvus Pharmaceuticals Shares Surge 7% After Positive Phase 1 Trial Results for Soquelitinib in Atopic Dermatitis - mediahousepress
Corvus Pharmaceuticals stock falls despite promising early trial results - Investing.com
Corvus Pharmaceuticals stock rebounds on positive trial results By Investing.com - Investing.com Canada
Corvus Pharmaceuticals Announces Interim Data from - GlobeNewswire
Form 8-K Corvus Pharmaceuticals, For: Dec 18 - StreetInsider.com
Corvus Pharma's Atopic Dermatitis Drug Shows Promising 69% Efficacy in Phase 1 Trial Data - StockTitan
Why US Futures Are Rising WednesdayCorvus Pharma (NASDAQ:CRVS), Applied DNA Sciences (NASDAQ:APDN) - Benzinga
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket - Benzinga
Corvus to share soquelitinib trial data for skin condition By Investing.com - Investing.com Australia
Corvus Pharmaceuticals Inc (CRVS) 財務データ
収益
当期純利益
現金流量
EPS
0.65%
4.62%
大文字化:
|
ボリューム (24 時間):